Monopar Therapeutics Inc. (MNPR)
Market Cap | 12.59M |
Revenue (ttm) | n/a |
Net Income (ttm) | -7.61M |
Shares Out | 17.48M |
EPS (ttm) | -0.52 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 45,273 |
Open | 0.730 |
Previous Close | 0.741 |
Day's Range | 0.711 - 0.757 |
52-Week Range | 0.274 - 1.730 |
Beta | 1.15 |
Analysts | Strong Buy |
Price Target | 2.00 (+177.78%) |
Earnings Date | Aug 8, 2024 |
About MNPR
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops MNPR-101-Zr, a clinical stage urokinase plasminogen activator receptor-targeted radiodiagnostic imaging agent; and MNPR-101-RIT, a late preclinical stage radiotherapeutic for advanced cancers. It also develops Camsirubicin, a Phase 1b clinical stage novel analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; and MNP... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for MNPR stock is "Strong Buy." The 12-month stock price forecast is $2.0, which is an increase of 177.78% from the latest price.
News
![](https://cdn.snapi.dev/images/v1/9/c/press10-2494877.jpg)
Monopar Announces MNPR-101-RIT Abstract Accepted as a Top-Rated Oral Presentation at EANM'24
WILMETTE, Ill., June 25, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharma company focused on developing innovative treatments for cancer patients, today ...
![](https://cdn.snapi.dev/images/v1/i/h/press5-2472963.jpg)
Monopar and NorthStar Amend & Extend Collaboration
Highlights: Builds on Companies' respective core strengths Aligns intellectual property rights Establishes a long-term supply agreement under which NorthStar provides actinium-225 for Monopar's develo...
![](https://cdn.snapi.dev/images/v1/d/k/press6-2470843.jpg)
Monopar Presents Data Showcasing the Appeal of uPAR as a Radiopharma Cancer Target and of its lead Clinical Program at the 2024 SNMMI Annual Meeting
WILMETTE, Ill., June 10, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharmaceutical company focused on developing innovative treatments for cancer patients...
![](https://cdn.snapi.dev/images/v1/y/g/press13-2447048.jpg)
Monopar Announces CFO Succession
WILMETTE, Ill., May 24, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharmaceutical company focused on developing innovative treatments for cancer patients,...
![](https://cdn.snapi.dev/images/v1/v/g/press14-2420439.jpg)
Monopar Therapeutics Reports First Quarter 2024 Financial Results and Strategic Focus on its Radiopharma Pipeline
Initiated MNPR-101-Zr First-in-Human Phase 1 Radiopharma Clinical Trial MNPR-101-RIT Phase 1 Clinical Trial Targeted for Launch as Early as Q4 2024 or Q1 2025 WILMETTE, Ill., May 09, 2024 (GLOBE NEWSW...
![](https://cdn.snapi.dev/images/v1/q/p/press2-2377918.jpg)
Monopar Announces Radiopharma Presentation Selected for Society of Nuclear Medicine and Molecular Imaging 2024 Annual Meeting
WILMETTE, Ill., April 18, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients,...
![](https://cdn.snapi.dev/images/v1/c/8/press5-2364987.jpg)
Monopar Initiates Radiopharma Phase 1 Clinical Trial for MNPR-101-Zr in Advanced Cancer Patients
WILMETTE, Ill., April 10, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients,...
![](https://cdn.snapi.dev/images/v1/k/l/press11-2345728.jpg)
Monopar Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Developments
WILMETTE, Ill., March 28, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients,...
![](https://cdn.snapi.dev/images/v1/k/d/press2-2308052.jpg)
Monopar Announces Positive Preclinical Therapeutic Isotope Data for its MNPR-101 Radiopharma Program
WILMETTE, Ill., March 05, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients,...
![](https://cdn.snapi.dev/images/v1/z/g/press8-2295380.jpg)
Monopar Provides Update on MNPR-101-Zr Radiopharma Clinical Trial
WILMETTE, Ill., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, ...
![](https://cdn.snapi.dev/images/v1/b/s/press1-2283275.jpg)
Monopar Receives Clearance to Proceed with First-in-Human Phase 1 Trial of Novel Radiopharmaceutical MNPR-101-Zr in Advanced Cancers
WILMETTE, Ill., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, ...
![](https://cdn.snapi.dev/images/v1/d/b/press13-2149288.jpg)
Monopar Therapeutics Reports Third Quarter 2023 Financial Results and Recent Developments
MNPR-101 Radiopharma Program to Enter First-in-Human Studies Potentially As Early As December of This Year Camsirubicin Phase 1b Trial Efficacy and Safety Data Highlighted at the 2023 CTOS Annual Meet...
![](https://cdn.snapi.dev/images/v1/j/l/press16-2132355.jpg)
Monopar Presents Data Showing Tumor Reduction Benefit of Camsirubicin from Ongoing Phase 1b at the 2023 Connective Tissue Oncology Society (CTOS) Annual Meeting
WILMETTE, Ill., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend...
![](https://cdn.snapi.dev/images/v1/u/q/press13-2096339.jpg)
Monopar to Participate in the Roth MKM 2023 Healthcare Opportunities Conference
WILMETTE, Ill., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, ...
![](https://cdn.snapi.dev/images/v1/j/l/press6-2016743.jpg)
Monopar Therapeutics Reports Second Quarter 2023 Financial Results and Recent Developments
Camsirubicin Phase 1b Trial Currently at 5th Dose-Level (650 mg/m 2), Generating Encouraging Results MNPR-101 Radiopharma Program Advancing Toward First-in-Human Studies
![](https://cdn.snapi.dev/images/v1/w/i/press1-1941960.jpg)
Monopar to Participate in the Radiopharma Forum by the Lake 2023
WILMETTE, Ill., June 21, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, ...
![](https://cdn.snapi.dev/images/v1/7/0/conf2-1933280.jpg)
Monopar to Participate in the Maxim Group's Healthcare Virtual Conference
WILMETTE, Ill., June 14, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, ...
![](https://cdn.snapi.dev/images/v1/q/m/press16-1884614.jpg)
Monopar Therapeutics Reports First Quarter 2023 Financial Results and Recent Developments
Camsirubicin Phase 1b DoseEscalation Trial Enrolling 5th DoseLevel Cohort (650 mg/m2) MNPR-101 RIT Shows Promising Imaging and Therapeutic Preclinical Study Results Camsirubicin Phase 1b DoseEscala...
![](https://cdn.snapi.dev/images/v1/y/f/conf2-1814717.jpg)
Monopar to Present at the Jefferies Radiopharma Innovation Summit
WILMETTE, Ill., March 28, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to exten...
![](https://cdn.snapi.dev/images/v1/p/k/press17-1814257.jpg)
Monopar Announces Result of Interim Analysis of Phase 2b/3 VOICE Trial Evaluating Validive for Severe Oral Mucositis
WILMETTE, Ill., March 27, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to exten...
![](https://cdn.snapi.dev/images/v1/c/l/press2-1809319.jpg)
Monopar Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Recent Developments
Validive ® Phase 2b/3 VOICE Trial Anticipates Go/No-Go Interim Readout by End of Next Week Camsirubicin Phase 1b Dose-Escalation Trial Now Enrolling 5th Dose-Level Cohort (650 mg/m 2)
![](https://cdn.snapi.dev/images/v1/3/n/conf17-1785080.jpg)
Monopar to Present at the 35th Annual Roth Conference
WILMETTE, Ill., March 07, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to exten...
![](https://cdn.snapi.dev/images/v1/x/b/press16-1771724.jpg)
Monopar and NorthStar Announce Expanded Radiopharma Program, Positive Preclinical Results, and Visibility Toward Human Trials
WILMETTE, Ill. and BELOIT, Wis., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) (Wilmette, Ill.) and NorthStar Medical Radioisotopes, LLC (Beloit, Wis.), today announced an...
![](https://cdn.snapi.dev/images/v1/v/s/press1-1752415.jpg)
Monopar Announces Camsirubicin Clinical Program Update - Improved Side Effect Profile Seen to Date Compared to Doxorubicin
WILMETTE, Ill., Feb. 14, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend...
![](https://cdn.snapi.dev/images/v1/5/q/press19-1724081.jpg)
Monopar Announces Projected Timeline of Upcoming Q1 2023 Data Events for Validive, Camsirubicin, and MNPR-101 RIT
WILMETTE, Ill., Jan. 26, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend...